Overview

• All patients treated with CT-388 lost at least 5% of their weight, with 45% losing over 20%.
• The drug mimics gut hormones GLP-1 and GIP to suppress appetite and control blood sugar.
• Mild to moderate gastrointestinal side effects were the most common adverse events reported.
• Roche's stock rose by 4% following the announcement of the trial results.
• The company aims to develop CT-388 for both obesity and type 2 diabetes treatment.